Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors

PURPOSE. To evaluate the maximum tolerated regimen (MTR), dose-limiting toxicities, and pharmacokinetics of pazopanib, an oral small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit, in combination with paclitaxel....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Tan, Antoinette R., Dowlati, Afshin, Jones, Suzanne F., Infante, Jeffrey R., Nishioka, Jennifer, Fang, Lei, Hodge, Jeffrey P., Gainer, Shelby D., Arumugham, Thangam, Suttle, A. Benjamin, Dar, Mohammed M., Lager, Joanne J., Burris, Howard A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2010
Aiheet:
Clinical Pharmacology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227920/
https://ncbi.nlm.nih.gov/pubmed/21147873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0095
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia